Preclinical Profiles of SKB264, a Novel Anti-TROP2 Antibody Conjugated to Topoisomerase Inhibitor, Demonstrated Promising Antitumor Efficacy Compared to IMMU-132

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 9

PMID 36620535

Authors

Yezhe Cheng

Xiaoxi Yuan

Qiang Tian

Xiuying Huang

Yang Chen

Yuzhi Pu

Hu Long

Mingyu Xu

Yafei Ji

Jia Xie

Yuping Tan

Xi Zhao

Hongmei Song

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to improve the intratumoral accumulation of an antibody-drug conjugate (ADC) and minimize its off-target toxicity, SKB264, a novel anti-trophoblast antigen 2 (TROP2) ADC that was developed using 2-methylsulfonyl pyrimidine as the linker to conjugate its payload (KL610023), a belotecan-derivative topoisomerase I inhibitor. The preclinical pharmacologic profiles of SKB264 were assessed in this study.

Methods: The and pharmacologic profiles of SKB264, including efficacy, pharmacokinetics-pharmacodynamics (PK-PD), safety, and tissue distribution, were investigated using TROP2-positive cell lines, cell-derived xenograft (CDX), patient-derived xenograft (PDX) models, and cynomolgus monkeys. Moreover, some profiles were compared with IMMU-132.

Results: , SKB264 and SKB264 monoclonal antibody (mAb) had similar internalization abilities and binding affinities to TROP2. After cellular internalization, KL610023 was released and inhibited tumor cell survival. , SKB264 significantly inhibited tumor growth in a dose-dependent manner in both CDX and PDX models. After SKB264 administration, the serum or plasma concentration/exposure of SKB264 (conjugated ADC, number of payload units ≥1), total antibody (Tab, unconjugated and conjugated mAb regardless of the number of the payload units), and KL610023 in cynomolgus monkeys increased proportionally with increasing dosage from 1 to 10 mg/kg. The linker stability of SKB264 was significantly enhanced as shown by prolonged payload half-life (SKB264 . IMMU-132, 56.3 h . 15.5 h). At the same dose, SKB264's exposure in tumor tissue was 4.6-fold higher than that of IMMU-132.

Conclusions: Compared with IMMU-132, the longer half-life of SKB264 had a stronger targeting effect and better antitumor activity, suggesting the better therapeutic potential of SKB264 for treating TROP2-positive tumors.

Citing Articles

Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review.

Yamanaka T, Nishikawa T, Yoshida H Cells. 2025; 14(5).

PMID: 40072062 PMC: 11898814. DOI: 10.3390/cells14050333.

Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.

Jiang K, Wang S Transl Breast Cancer Res. 2025; 6:9.

PMID: 39980806 PMC: 11836745. DOI: 10.21037/tbcr-24-38.

A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy.

Xi X, Wang Y, An G, Feng S, Zhu Q, Wu Z Acta Pharm Sin B. 2024; 14(11):4806-4818.

PMID: 39664437 PMC: 11628804. DOI: 10.1016/j.apsb.2024.08.023.

[Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer].

Xu J, Liu J, Mei S, Zhou Q Zhongguo Fei Ai Za Zhi. 2024; 27(10):763-776.

PMID: 39631833 PMC: 11629093. DOI: 10.3779/j.issn.1009-3419.2024.101.25.

Antibody-Drug Conjugates: A Start of a New Era in Gynecological Cancers.

Fasih S, Welch S, Lohmann A Curr Oncol. 2024; 31(11):7088-7106.

PMID: 39590153 PMC: 11593302. DOI: 10.3390/curroncol31110522.

References

McDougall A, Tolcos M, Hooper S, Cole T, Wallace M . Trop2: from development to disease. Dev Dyn. 2014; 244(2):99-109. DOI: 10.1002/dvdy.24242. View

Shvartsur A, Bonavida B . Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015; 6(3-4):84-105. PMC: 4426947. DOI: 10.18632/genesandcancer.40. View

Roy P, Saikia B . Cancer and cure: A critical analysis. Indian J Cancer. 2017; 53(3):441-442. DOI: 10.4103/0019-509X.200658. View

Kulschewski T, Pleiss J . Binding of Solvent Molecules to a Protein Surface in Binary Mixtures Follows a Competitive Langmuir Model. Langmuir. 2016; 32(35):8960-8. DOI: 10.1021/acs.langmuir.6b02546. View

Wu B, Yu C, Zhou B, Huang T, Gao L, Liu T . Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells. Exp Ther Med. 2017; 14(3):1947-1952. PMC: 5609167. DOI: 10.3892/etm.2017.4788. View

Pandey R, Gruslova A, Chiou J, Brenner A, Tiziani S . Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan). Anal Chem. 2019; 92(1):1260-1267. DOI: 10.1021/acs.analchem.9b04419. View

Chang C, Wang Y, Li R, Rossi D, Liu D, Rossi E . Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Res. 2017; 77(19):5384-5394. DOI: 10.1158/0008-5472.CAN-16-3431. View

Kubizek F, Eggenreich B, Spadiut O . Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?. Protein Pept Lett. 2017; 24(8):686-695. DOI: 10.2174/0929866524666170724105211. View

Cubas R, Li M, Chen C, Yao Q . Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009; 1796(2):309-14. DOI: 10.1016/j.bbcan.2009.08.001. View

10.

Lee J, Lee J, Kim J, Ahn S, Lee S, Kim M . Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1999; 21(5):581-90. DOI: 10.1007/BF02975379. View

11.

Andersson S, Antonsson M, Elebring M, Jansson-Lofmark R, Weidolf L . Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discov Today. 2018; 23(10):1733-1745. DOI: 10.1016/j.drudis.2018.05.030. View

12.

Bednova O, Leyton J . Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?. Int J Mol Sci. 2020; 21(19). PMC: 7582582. DOI: 10.3390/ijms21197268. View

13.

SANDS H, Jones P . Methods for the study of the metabolism of radiolabeled monoclonal antibodies by liver and tumor. J Nucl Med. 1987; 28(3):390-8. View

14.

Chen E, Jonker D, Siu L, McKeever K, Keller D, Wells J . A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. Invest New Drugs. 2016; 34(4):450-7. DOI: 10.1007/s10637-016-0351-x. View

15.

Trail P, Dubowchik G, Lowinger T . Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2017; 181:126-142. DOI: 10.1016/j.pharmthera.2017.07.013. View

16.

Hammood M, Craig A, Leyton J . Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel). 2021; 14(7). PMC: 8308841. DOI: 10.3390/ph14070674. View

17.

Sun X, Ponte J, Yoder N, Laleau R, Coccia J, Lanieri L . Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Bioconjug Chem. 2017; 28(5):1371-1381. DOI: 10.1021/acs.bioconjchem.7b00062. View

18.

Hafeez U, Parakh S, Gan H, Scott A . Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020; 25(20). PMC: 7587605. DOI: 10.3390/molecules25204764. View

19.

Sharkey R, McBride W, Cardillo T, Govindan S, Wang Y, Rossi E . Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clin Cancer Res. 2015; 21(22):5131-8. DOI: 10.1158/1078-0432.CCR-15-0670. View

20.

Stepan L, Trueblood E, Hale K, Babcook J, Borges L, Sutherland C . Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59(7):701-10. PMC: 3201164. DOI: 10.1369/0022155411410430. View